Jump to main content
Jump to site search

Issue 12, 2016
Previous Article Next Article

Membranolytic anticancer peptides

Author affiliations


Membranolytic anticancer peptides (ACPs) potentially offer new perspectives for the development of anticancer drugs. Their receptor-independent mechanisms of action hold the promise to hinder the development of resistance, which is a hurdle of many present-day chemotherapeutics. Peptide selectivity for cancer cells is believed to be primarily due to a net charge difference between neoplastic and non-neoplastic cells at the membrane surface. However, their exact molecular mechanisms are not yet fully understood. In this review, we summarise the state of the art of membranolytic ACP research and discuss the molecular features that have been related to the structure–activity relationships of alpha-helical ACPs.

Graphical abstract: Membranolytic anticancer peptides

Back to tab navigation

Publication details

The article was received on 07 Jul 2016, accepted on 02 Sep 2016 and first published on 15 Sep 2016

Article type: Review Article
DOI: 10.1039/C6MD00376A
Med. Chem. Commun., 2016,7, 2232-2245

  •   Request permissions

    Membranolytic anticancer peptides

    G. Gabernet, A. T. Müller, J. A. Hiss and G. Schneider, Med. Chem. Commun., 2016, 7, 2232
    DOI: 10.1039/C6MD00376A

Search articles by author